Growth hormone (GH) and prolactin (PRL) qualify as lymphohaemopoietic
growth and differentiation factors, and so does insulin-like growth fa
ctor (IGF)-I, which mediates many of GH activities. Although there is
only limited evidence that endocrine, paracrine or autocrine GH or PRL
play a role in human leukaemia and lymphoma, the expression of these
factors or their receptors may have diagnostic or therapeutic implicat
ions. Indeed, the participation of GH, PRL or IGF-I in the development
or progression of certain haematological malignancies or to the antit
umour immune response has been documented. Examples discussed in this
review include a rat lymphoma in which the PRL receptor acts as an onc
ogene; the rat Nb2 lymphoma, which is dependent on PRL for growth; and
experiments showing that PRL stimulates natural killer cell activity
and the development of lymphokine-activated killer cells.